Inventor · disambiguated record
George Kopsidas
Also filed as: KOPSIDAS GEORGE
9 granted patents·16 pending applications·32 citations·filing 2005–2025
85Inventor score
Files withTEVA PHARMACEUTICALS AUSTRALIA PTY LTD7IMUNEXUS THERAPEUTICS LTD3BEMBRIDGE GARY PETER2COIA GREGORY2GLAXO GROUP LTD2
Top patents by PatentIndex Score
25 records- 0190US10822422B2Antibodies against TL1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Granted Nov 3, 2020·10 cites·13 claims
- 0287US2025353919A1Antibodies Against TL1A and Uses ThereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2025·Application pending·0 cites
- 0385US8563697B2Anti-IL-12/IL-23 antibodiesCLARKE ADAM WILLIAM·Filed 2009·Granted Oct 22, 2013·11 cites·11 claims
- 0483US12410256B2Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseasesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2023·Granted Sep 9, 2025·0 cites·19 claims
- 0583US8362208B2ImmunoglobulinsGLAXO GROUP LTD·Filed 2006·Granted Jan 29, 2013·6 cites·2 claims
- 0673US11345736B2Multi-specific moleculesIMUNEXUS THERAPEUTICS LTD·Filed 2021·Granted May 31, 2022·1 cites·21 claims
- 0770US7612169B2Osteoprotegerin variant proteinsEVOGENIX LTD·Filed 2005·Granted Nov 3, 2009·3 cites·81 claims
- 0868US2021347904A1Antibodies against tl1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2020·Application pending·0 cites
- 0966US8530624B2Osteoprotegerin variant proteinsROBERTS ANTHONY·Filed 2009·Granted Sep 10, 2013·1 cites·21 claims
- 1066US2024182542A1Multi-Specific MoleculesIMUNEXUS THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1164US2014255302A1ANTIBODIES AGAINST TL1a AND USES THEREOFTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
- 1258US2009311710A1Mutagenesis methods using ribavirin and/or rna replicasesCOIA GREGORY·Filed 2009·Application pending·0 cites
- 1355US2025345423A1Binding domain molecules on cell surfacesIMUNEXUS THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1454US2021040177A1Multi-Specific MoleculesIMUNEXUS PTY LTD·Filed 2020·Application pending·0 cites
- 1553US11542339B2Anti-CD43 antibody and use thereof for cancer treatmentAPROGEN MEDICINES INC·Filed 2020·Granted Jan 3, 2023·0 cites·9 claims
- 1652US2014086922A1Anti-il-12/il-23 antibodiesCEPHALON AUSTRALIA PTY LTD·Filed 2013·Application pending·0 cites
- 1751US10676531B2Anti-CD43 antibody and use thereof for cancer treatmentAPROGEN KIC INC·Filed 2016·Granted Jun 9, 2020·0 cites·7 claims
- 1851US2011206686A1Il-23 antibodiesBEMBRIDGE GARY PETER·Filed 2008·Application pending·0 cites
- 1951US2009123479A1ImmunoglobulinsBEMBRIDGE GARY PETER·Filed 2008·Application pending·0 cites
- 2048US2013287781A1ImmunoglobulinsGLAXO GROUP LTD·Filed 2013·Application pending·0 cites
- 2147US2016264661A1Anti-il-12/il-23 antibodiesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
- 2247US2005266453A1Mutagenesis methods using ribavirin and/or RNA replicasesCOIA GREGORY·Filed 2005·Application pending·0 cites
- 2346US2019338013A1Multi-Specific MoleculesIMUNEXUS PTY LTD·Filed 2017·Application pending·0 cites
- 2442US2014286957A1ANTIBODIES TO CD1dTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
- 2526US2012093811A1Anti-vegf-d antibodiesSIMMONDS JASON W·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when George Kopsidas files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →